Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Novel Major Depression Drug Misses in Phase 3 Topline ResultsThe novel drug SAGE-217 did not meet its primary outcome of reduction in depression scores at day 15 in the phase 3 MOUNTAIN trial, but additional analyses show "supportive" data, researchers say.
Not All Problem Drinkers Need AbstinenceFor the right patients, simple behavioral interventions can direct those who drink alcohol excessively back to moderation.
Medscape Medical News, December 6, 2019
New Biogen Data Showed No Major Safety Issues for Its Alzheimer's DrugBiogen Inc on Thursday presented new data on its experimental Alzheimer's drug aducanumab that did not reveal any new safety concerns as the U.S. biotech company made the case to researchers and investors about why it plans to seek U.S. approval after declaring the drug a failure in March.
